Literature DB >> 7569118

Rhabdomyolysis and acute renal failure during high-dose haloperidol therapy.

S J Marsh1, G M Dolson.   

Abstract

Severe adverse reactions to neuroleptic medications are not uncommon and include the neuroleptic malignant syndrome, rhabdomyolysis, and acute renal failure. The neuroleptic malignant syndrome consists of hyperthermia, diaphoresis, tachycardia, tachypnea, abnormal blood pressure, alteration of consciousness, and extrapyramidal rigidity. Rhabdomyolysis--which might be due to hyperthermia, muscle rigidity, and/or metabolic changes in skeletal muscle function--results in acute renal failure. We report a patient with rhabdomyolysis and acute renal failure that developed after large doses of haloperidol were given, but without muscle rigidity or hyperthermia. This patient's presentation illustrates that high-dose haloperidol therapy might cause rhabdomyolysis and acute renal failure without significant rigidity or hyperthermia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7569118     DOI: 10.3109/08860229509037611

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  3 in total

1.  Rhabdomyolysis with erratic serum creatinin phosphokinase levels: intramuscular injection of haloperidol decanoate.

Authors:  Premnath Reddy Karre; Jeetinder Gujral; Ernesto Rodriguez
Journal:  BMJ Case Rep       Date:  2009-08-17

2.  A Case of Exacerbation of Haloperidol-Induced Rhabdomyolysis Following the Onset of COVID-19.

Authors:  Keisuke Takada; Yukiyoshi Sada; Masaru Samura; Masashi Matsuura; Naoki Hirose; Takenori Kurata; Fumio Nagumo; Junichi Ishii; Sakura Koshioka; Masaki Uchida; Junki Inoue; Koji Tanikawa; Hiroyuki Kunishima
Journal:  Am J Case Rep       Date:  2022-06-20

Review 3.  Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice.

Authors:  Zacharias G Laoutidis; Kanellos T Kioulos
Journal:  Psychopharmacology (Berl)       Date:  2014-10-16       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.